|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANKRD28 |
Gene summary for ANKRD28 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANKRD28 | Gene ID | 23243 |
| Gene name | ankyrin repeat domain 28 | |
| Gene Alias | CFAP79 | |
| Cytomap | 3p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | O15084 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23243 | ANKRD28 | CCI_2 | Human | Cervix | CC | 1.23e-09 | 1.15e+00 | 0.5249 |
| 23243 | ANKRD28 | CCI_3 | Human | Cervix | CC | 9.32e-06 | 7.49e-01 | 0.516 |
| 23243 | ANKRD28 | Tumor | Human | Cervix | CC | 8.02e-04 | -2.80e-01 | 0.1241 |
| 23243 | ANKRD28 | sample3 | Human | Cervix | CC | 3.48e-02 | -2.45e-01 | 0.1387 |
| 23243 | ANKRD28 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.20e-28 | -7.52e-01 | 0.0155 |
| 23243 | ANKRD28 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.02e-08 | -6.42e-01 | -0.1808 |
| 23243 | ANKRD28 | HTA11_2951_2000001011 | Human | Colorectum | AD | 2.18e-03 | -7.70e-01 | 0.0216 |
| 23243 | ANKRD28 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.30e-05 | -4.32e-01 | -0.0811 |
| 23243 | ANKRD28 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.19e-02 | -6.84e-01 | -0.2196 |
| 23243 | ANKRD28 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.99e-09 | -6.92e-01 | -0.1207 |
| 23243 | ANKRD28 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.76e-03 | -5.00e-01 | -0.1526 |
| 23243 | ANKRD28 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.16e-25 | -5.64e-01 | -0.1464 |
| 23243 | ANKRD28 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.01e-14 | -4.87e-01 | -0.1001 |
| 23243 | ANKRD28 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.03e-05 | -7.62e-01 | -0.2061 |
| 23243 | ANKRD28 | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.28e-04 | -7.99e-01 | -0.1462 |
| 23243 | ANKRD28 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.21e-05 | -6.66e-01 | -0.0179 |
| 23243 | ANKRD28 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.77e-21 | -7.49e-01 | 0.096 |
| 23243 | ANKRD28 | HTA11_4255_2000001011 | Human | Colorectum | SER | 8.14e-04 | -7.13e-01 | 0.0446 |
| 23243 | ANKRD28 | HTA11_7663_2000001011 | Human | Colorectum | SER | 1.34e-02 | -5.67e-01 | 0.0131 |
| 23243 | ANKRD28 | HTA11_10623_2000001011 | Human | Colorectum | AD | 4.78e-02 | -5.68e-01 | -0.0177 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANKRD28 | SNV | Missense_Mutation | c.2600N>A | p.Gly867Glu | p.G867E | O15084 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ANKRD28 | SNV | Missense_Mutation | c.1851G>C | p.Lys617Asn | p.K617N | O15084 | protein_coding | tolerated(0.09) | benign(0.098) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ANKRD28 | SNV | Missense_Mutation | c.1156G>A | p.Asp386Asn | p.D386N | O15084 | protein_coding | tolerated(0.1) | possibly_damaging(0.6) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| ANKRD28 | SNV | Missense_Mutation | rs750409900 | c.664G>C | p.Val222Leu | p.V222L | O15084 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| ANKRD28 | SNV | Missense_Mutation | c.691N>C | p.Asp231His | p.D231H | O15084 | protein_coding | deleterious(0.04) | benign(0.141) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ANKRD28 | SNV | Missense_Mutation | rs759982054 | c.64N>A | p.Asp22Asn | p.D22N | O15084 | protein_coding | deleterious(0.01) | possibly_damaging(0.821) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ANKRD28 | SNV | Missense_Mutation | novel | c.2929N>C | p.Ala977Pro | p.A977P | O15084 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ANKRD28 | SNV | Missense_Mutation | novel | c.1450N>T | p.Asp484Tyr | p.D484Y | O15084 | protein_coding | tolerated(0.34) | benign(0.055) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ANKRD28 | SNV | Missense_Mutation | c.3037G>A | p.Glu1013Lys | p.E1013K | O15084 | protein_coding | tolerated(0.81) | benign(0.005) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ANKRD28 | SNV | Missense_Mutation | c.3041N>T | p.Ala1014Val | p.A1014V | O15084 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |